Friday, 20 Oct 2017

You are here

The RheumNow Week in Review - 26 May 2017

Dr. Jack Cush Reviews highlights from the past week on RheumNow.com:

  1. Study of 24 erosive RA pts shows addition of anabolic teriparatide did not significantly reduce the rate/volume of erosions http://buff.ly/2rh1hsO
  2. Swedish study 27k+ AS, PsA and uSpA are at increased risk for Acute Coronary syndrome & stroke events https://t.co/Zq49quPo3T
  3. β-Defensin2 is a biomarker reflects IL-17A-driven skin dz in psoriasis, not PsA. Highly correlates w/ PASI & IL-17A https://t.co/JmCmMIN0Cq  Study of 8 pts controls the expression of 170 proteins in blood, nonlesional skin, and lesional skin
  4. Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses https://t.co/MxFR1wjl8N
  5. Claims data on 2495 JIA pts shows significantly more serious bacterial infx w/ TNFi use (HR 2.72) compared to DMARDs https://t.co/CKu9oIOzlj
  6. Among 323 ANCA-Assoc Vasculitis pts, CTX Rx(SIR 3.1) had 4.6 more cancers than RTX (SIR 0.67); RTX = pop Cancer rate https://t.co/NZnCbMOGQt
  7. Kevzara (Sarilumab) the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition https://t.co/mzIOOhEnMe https://t.co/2U3J2sskum
  8. FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis, based on GiACTA study. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL   PI says its to be given with a tapering course of steroids. https://t.co/SCaiX1FDQx
  9. ACR supports FDA draft on interchangeability, naming suffixes & Biosimilar User Fee Act; but not extrapolation- huh? https://t.co/5aKzmwul2N
  10. Survey of 364 UK RA pts shows that giving info on TNFi helps 1/3 and scares 1/3. Many misconceptions about safety https://t.co/lM8gxjjulk
  11. Dr Erkan says secondary THROMBOSIS prevention- Venous-rx warfarin keep INR 2-3; Arterial - warfarin keep INR 2-3 + ASA, or INR 3-4 w/o ASA
  12. Dr Forum Erkan says catastrophic antiphospholipid syndrome should be Rx with anticoagulation, steroids, IVIG w/ plasma exchange (+/- RTX)
  13. Anti-Sclerostin Drug -Romosozumab (EVENITY) Hampered by Heart Problems 
  14. Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis  
  15. NLRP3 Activation in Still's Disease 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.